

# The 15-Year Journey of the PIP Framework and the Evolving Landscape of GISRS

SARINet plus and REVELAC-i Regional Meeting

24-26 March 2026



World Health  
Organization



Framework



PIP Framework

15 years of strengthening pandemic influenza preparedness for a more equitable response


# A brief overview

Every year seasonal influenza kills **>290 000**  
– **650 000 people**

In the last 100+ years pandemic influenza  
has killed **~ 52 000 000 people**



# What is the PIP Framework?




A public health **Access and Benefit Sharing** system adopted by the World Health Assembly in 2011

- Developed after the re-emergence of avian influenza (H5N1) or 'bird flu' in the early 2000s and the perceived inequities in access to vaccines
- Brings together Member States, industry, civil society organizations, other key stakeholders & WHO

Two equally important objectives:

## 1 Virus sharing

Strengthen global influenza surveillance through timely sharing of influenza viruses with pandemic potential (**IVPP**) with the Global Influenza Surveillance and Response System (**GISRS**)



## 2 Benefit sharing

Increase equity of access to pandemic response measures such as vaccines

# How does the PIP Framework work?



Access



Countries share influenza viruses with pandemic potential (IVPPs) with GISRS



GISRS carries out risk assessment & analyses; recommends influenza vaccine composition & develops candidate vaccine viruses (CVVs)



Manufacturers use analyses, CVVs & information to produce influenza vaccines or other products

In return...



Benefit sharing



... countries receive risk assessments & information during interpandemic times, & donated vaccines and other supplies secured by WHO through the **SMTA2s**, based on public health risks and needs, **during a pandemic.**



... countries receive capacity strengthening for pandemic influenza preparedness and response through implementation of the annual **Partnership Contribution (PC)** (US\$33.7M/y\*)

*\*PC level updated to US\$33.7M from US\$28M in 2025*

# Benefit sharing: Two key mechanisms



## SMTA2 (Standard Material Transfer Agreement 2):

Legally binding contracts signed by WHO with recipients of PIP Biological Materials (PIP BM) to secure **real-time advance access to FUTURE pandemic response products**, such as vaccines and antivirals, to be donated to countries in need.




**SIGNED ONCE**



## PC (Partnership Contribution):

**Annual cash contribution to WHO from influenza vaccine, diagnostic & pharmaceutical manufacturers that use GISRS.** Funds are used **NOW** to strengthen pandemic preparedness capacities where they are weak & to build a response fund to be used for **FUTURE** pandemic influenza response.



**PAID ANNUALLY**

# What has been secured under the PIPF SMTAs2?



## ➤ **100 SMTA2 Agreements Signed**

Cat A — **Vaccine Mx: 16**

Cat B — **Diagnostics & Other pandemic products: 2**

Cat C — **Other institutions (e.g. academia): 82**



## ➤ **~900M doses\*** of real-time production which represents ~11% of future pandemic vaccine production



## ➤ **25M Syringes**

## ➤ **Up to 5M treatment courses**



## ➤ **250,000 diagnostic kits**

\*best case scenario based on current technologies; in first year of pandemic

# What has been achieved under Partnership Contribution (1)



➤ **US\$ 350M** collected




- **86** Countries Supported
- Work conducted at all **3 levels of WHO:** Country, Region, Global



➤ Progress against indicators and milestones, as per the [HLIP III M&E Framework](#), is reported in 4 reports per biennium. All reports are available online on the [PIP PC webpage](#).

## How are the PC funds distributed?



# What has been achieved under Partnership Contribution (2)



## ➤ Laboratory, Surveillance, risk assessment

- ❖ **National Influenza Centres (NICs).** 25 new NICs
- ❖ **Virus sharing**
  - ✓ 8 774 (2018—2024) zoonotic influenza viruses and other IVPPs characterized .
  - ✓ 22 new Member States (113 in 2014 vs 135 in 2024) sent shipments of influenza virus samples to WHO CCs.
- ❖ **Global reporting for surveillance.** 56 new Member States (61 in 2014 vs 117 in 2024) started or improved influenza reporting systems via global surveillance platform i.e. FluNet/FluID in GISRS.



## ➤ Risk communications and Community Engagement

- ❖ **OpenWHO.** OpenWHO online learning platform with a total of 34 influenza-related courses, over 189 597 users from 194 Member States (2018—2023).



## ➤ Burden of disease

- ❖ 61 Member States (as of 2024) published burden of disease estimates.



## ➤ Regulatory capacity strengthening

- ❖ 15 new Member States (1 in 2017 vs 16 in 2025) achieved Maturity level 3 in WHO's classification of regulatory authorities for medicines, confirming the presence of a stable, well-functioning, and integrated regulatory system, bringing the total to 16 Member States.

# Implementation partners



**WHO Member States:** heart of pandemic influenza preparedness & response providing guidance on PIP implementation when needed



**GISRS Institutions:** technical foundation of influenza detection, surveillance & global alert; share viruses and other critical information and materials



**Industry:** manufacture pandemic prevention, control and response products; contributes PC funds



**Civil society organizations:** ensure community engagement and equity as a driver, principle and outcome



**WHO & development partners,** including academia, foundations, and specialized institutions: promote influenza preparedness and response

# Governance of PIP Framework

The PIP Framework is overseen through a three-pillared governance structure



## PIP governance structure



### World Health Assembly *Oversees implementation*

- Oversees implementation of the PIPF
- Receives reports from the WHO Director-General
- Provides overall policy direction



### WHO Director-General *Promotes implementation*

- Responsible for promoting implementation of the PIPF
- Receives recommendations and guidance from PIP Advisory Group
- Reports to Member States



### PIP Advisory Group *Monitors implementation*

- 18 experts drawn from Member States across all WHO regions
- Provides evidence-based recommendations and guidance to the WHO Director-General to strengthen the functioning of the PIPF

**Thank You to all the PIP partners throughout these past  
15 years**

- **Member States**
- **GISRS**
- **Industry & Associations**
- **Civil Society Organizations**
- **Other Partners**
- **WHO Staff across all levels of the Organization**



**Nothing would have been possible without you!**

# Contact

## PIP Framework

Epidemic and Pandemic Threat Management  
WHO Health Emergencies Programme  
email [pipframework@who.int](mailto:pipframework@who.int)

## World Health Organization

20 Avenue Appia  
1211 Geneva 27  
Switzerland

# A 15-Year Journey of PIP Framework and the Evolving Landscape of GISRS


Anne Huvos & Wenqing Zhang






# Constant pandemic risk

- Vast reservoir in wild aquatic birds
- Avian influenza endemic in domestic poultry
- Swine influenza circulating in pigs




- Increasing spillover across species



# Multi-dimensional and substantial burden

- Example of avian influenza A(H5)



# Multi-dimensional and substantial burden


- Example of avian influenza A(H5)

## Poultry industry, livelihoods, food security




**+633 million**  
poultry lost since 2005  
(146 million in 2022)

## Global market and Trade



**48 billion USD**  
global poultry market  
disrupted

## Wildlife and biodiversity



**>50,000**  
marine mammals lost  
during 2023


## Public Health



**48% case-fatality** rate  
in humans (H5N1)

# Combating influenza requires global approach

- Click to add text
  - Second level
    - Third level
      - *Fourth level*
        - *Fifth level*



Courtesy of Drs. K.Gopal Murti and Robert Webster  
St Jude Children's Research Hospital of Memphis , Tennessee, USA.

# GISRS – since 1952

**1953 - 54 NICs\* in 42 countries**



**2026 - 158 NICs\* in 139 countries**



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data source: WHO Global Influenza Programme  
Map creation date: 21 March 2024  
Map production: WHO Global Influenza Programme



© WHO 2024. All rights reserved.

- **Since 1952:** seasonal influenza
- **Since 1997:** + avian influenza, variant/swine influenza, pandemic influenza




**New subtypes, new genetic & antigenic variants**

- **Since 2015:** ++ RSV
- **Since 2020:** +++ SARS-CoV-2

\* NICs: National Influenza Centres

# GISRS capacity building since 2011



**Member States adopted the PIP Framework in WHA 2011**



**GISRS  
hosting countries**

**Other countries**



**Many others  
not listed here**

# GISRS capacity building since 2011

An example: virus sharing


Countries, areas and territories made virus shipments to WHO CCs  
(data source: WHO CCs)



**116 → 126** Countries, areas and territories

**665 → 1271** Shipments





Countries, areas and territories made virus shipments to WHO CCs  
(data source: WHO CCs)



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

# GISRS capacity building since 2011



An example: candidate vaccine viruses



SMTA 2 of PIP Framework

# GISRS capacity building since 2011

An example: surveillance & vaccine composition



Partnership Contribution of PIP Framework

# Evolving landscape

GISRS-related

- Global – One Health
- Timely
- Continuous

## Opportunities

- **National Security Attention**  
Growing investment as influenza gains strategic importance
- **One Health in Action**  
Cross-sector collaboration becoming operational
- **Integrated Approaches**  
Systems increasingly connected across domains
- **Public Health Leadership**  
Strong awareness and momentum from health authorities

## Challenges

- **Fragmented Global Efforts**  
Coordination remains uneven
- **Divergent Objectives**  
Stakeholders pursue different priorities
- **Risk of Superficiality**  
Pathogen-agnostic models may dilute efforts needed for specific high-risk threats
- **Resource Competition**  
Funding and capacity stretched across agendas

# Evolving landscape

GISRS-related

- Global – One Health
- Timely
- Continuous

## Opportunities

- **Pandemic Agreement Momentum**  
Adoption at WHA and ongoing Pathogen Access and Benefit-Sharing (PABS) discussions for greater equity and access
- **Strategic Global Framework**  
Global Influenza Strategy (2019–2030) driving systematic, coordinated action
- **Established Global Architecture**  
Global Influenza Programme (GIP) – a long-standing mechanism coordinating GISRS since its establishment in 1952

## Challenges

- **System Uncertainty**  
Unclear implications to well – functioning PIP Framework and GISRS, especially on sharing of viruses and genetic sequence data
- **Geopolitical Headwinds**  
Conflicts and crises undermining global collaboration and implementation
- **Fragile Coordination**  
WHO's financial pressures risk weakening the GIP's global leadership; the global coordination of GISRS is hard-won and not readily replicable by any actor

# Evolving landscape

GISRS-related

- Global – One Health
- Timely
- Continuous


## Opportunities

- **Next-Generation Vaccine Platforms**  
mRNA and other emerging technologies provide innovative avenues for strengthening influenza preparedness
- **AI-Enabled Transformation**  
Big data and AI are driving a new wave of analytical and operational capabilities

## Challenges

- **Operational Integration**  
Ensuring new vaccine platforms complement - rather than disrupt - existing influenza systems and seasonal vaccine workflows
- **AI Reliability Risks**  
Gaps in basic scientific understanding may shape or bias AI models, raising concerns as reliance on these tools expands across sectors, including policy decision-making

# Summary



- **PIP Framework: *the world's (only) fully operational PABS mechanism***, functioning effectively for influenza since 2011 – **Happy 15<sup>th</sup> Anniversary !!**
- **GISRS: a proven, purpose-built system, *the longest-standing global network for systematic surveillance and response to infectious diseases***
  - Built on a clear mandate for influenza, with demonstrated capacity to expand to **other respiratory viruses** when needed
  - A global public good - essential for **influenza** today and for future “**Disease X**”
- **GISRS-PIP: real-world *successful model*** informing broader PABS negotiations
- **A critical moment:** full of opportunities, which comes with challenges



# Acknowledgements

- **Global Influenza Surveillance and Response System**
  - Members of GISRS
  - GISRS hosting countries and other countries
  - GISRS collaborators, donor agencies, and other partners
- **Public & private sectors, and academia contributing to the implementation of PIP Framework and Global Influenza Strategy**
- **WHO programmes and teams**
  - Global Influenza Programme
  - PIP Framework Secretariat
  - WHO Regional Offices
  - Other WHO teams



*Muchas gracias*

*Thank You*